Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Arginine methyltransferase inhibitors and uses thereof
Epizyme, Inc.
October 12, 2017 - N°20170291905

Described herein are compounds of formula (s-i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
Quinolones as inhibitors of class iv bromodomain proteins
Ucl Business Plc
October 12, 2017 - N°20170291875

The present invention provides compounds of formula (i) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:
Process for the manufacture of idalopirdine via hydrogenation of an imine
H. Lundbeck A/s
October 12, 2017 - N°20170291874

The present invention relates to the preparation of n-(2-(6-fluoro-1h-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (compound i), inn-name idalopirdine, and pharmaceutically acceptable salts thereof:
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of hepatitis c virus
Asana Biosciences, Llc
October 12, 2017 - N°20170290827

As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
Small molecule therapies for pulmonary hypertension
Creighton University
October 12, 2017 - N°20170290819

The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.
Benzomorphan analogs and the use thereof
Purdue Pharma L.p.
October 12, 2017 - N°20170290816

In one aspect, the invention provides compounds of formula (i) or (ii): (i) or (ii) and pharmaceutically acceptable salts and solvates thereof, wherein r1, r2a, r2b, r3, r4, z and g are defined as set forth in the disclosure. The invention also provides compounds of formulae a and b and pharmaceutically acceptable salts and solvates thereof. Other aspects ...
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Soluble c5ar antagonists
National Institute Of Biological Sciences, Beijing
October 05, 2017 - N°20170283446

Including stereoisomers and pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Carm1 inhibitors and uses thereof
Epizyme, Inc.
October 05, 2017 - N°20170283440

Provided herein are compounds of formula (i): (i) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein x, r1, r2a, r2b, r2c, r2d, are as defined herein, and ring het is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of ...
Macrocyclic compounds as trk kinase inhibitors
Array Biopharma, Inc.
October 05, 2017 - N°20170283435

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Pyrazolopyrimidine jak inhibitor compounds and methods
Genentech, Inc.
October 05, 2017 - N°20170283424

A compound of formula i, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are defined herein, are useful as inhibitors of one or more janus kinases. A pharmaceutical composition that includes a compound of formula i and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease ...
Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
October 05, 2017 - N°20170283416

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt ...
Diamide macrocycles that are fxia inhibitors
Bristol-myers Squibb Company
October 05, 2017 - N°20170283403

The present invention provides compounds of formula (i) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the ...
Arginine methyltransferase inhibitors and uses thereof
Epizyme, Inc.
October 05, 2017 - N°20170283400

Provided herein are various compounds, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Benzoquinone derivatives for treatment of cancer and methods of making the benzoquinone derivatives
Epizyme, Inc.
October 05, 2017 - N°20170283366

And to pharmaceutically acceptable salts or solvates thereof. In formula (i) one of x or y is hydrogen and the other one of x or y is 3-trifluoro-methylaniline; 3,4,5-trifluoroaniline; 4-methoxylaniline; 4-fluoroaniline; 3,3′-dimethyl-1,1′-biphenyl-4,4′-diamine; 2-(pyrrolidin-l-yl)ethyl)amine; 4-trifluoromethyl-benzylamine ; 4-fluorobenzyl-amine; 3,4-dimethoxybenzylamine; or 3,5-ditrifluoromethyl-benzylamine. Compounds of formula (i) have been identified as being useful in the treatment of ...
Novel compositions and therapeutic methods
Ayuvis Research Llc
October 05, 2017 - N°20170281667

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (ra), atherosclerosis, inflammatory bowel diseases (ibd), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, ...
Pyrimidinedione compounds
Myokardia, Inc.
October 05, 2017 - N°20170281626

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (hcm) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating hcm and other forms of heart disease.
Morphinan compounds
Concert Pharmaceuticals, Inc.
October 05, 2017 - N°20170281616

This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has nmda antagonist activity.
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
Hoffmann-la Roche Inc.
October 05, 2017 - N°20170281567

The instant invention relates to therapeutic combinations of lsd1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (sclc).
Arginine methyltransferase inhibitors and uses thereof
Epizyme, Inc.
October 05, 2017 - N°20170280720

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170275302

The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt ...
Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170275298

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt ...
Loading